Generation of a Potential Prognostic Matrix for Papillary Thyroid Cancer that Assesses Age, Tumor Size, Transforming Growth Factor-β, and BRAFV600E Mutation

2017 ◽  
Vol 40 (10) ◽  
pp. 586-592
Author(s):  
Ping Wang ◽  
Yu Lun ◽  
Yudong Fu ◽  
Fei Wang ◽  
Shihua Zhao ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Growth Factor ◽  
Papillary Thyroid Cancer ◽  
Tumor Size ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Papillary Thyroid

scholarly journals Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance

2020 ◽  
Vol 295 (31) ◽  
pp. 10726-10740
Author(s):  
Hongwei Gao ◽  
Peirong Bai ◽  
Lin Xiao ◽  
Mengjia Shen ◽  
Qiuxiao Yu ◽  
...  
Keyword(s):  
Cell Migration ◽  
Thyroid Cancer ◽  
Growth Factor ◽  
Sodium Iodide ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Mediator Complex ◽  
Papillary Thyroid ◽  
Sodium Iodide Symporter

Mediator complex subunit 16 (MED16) is a component of the mediator complex and functions as a coactivator in transcriptional events at almost all RNA polymerase II–dependent genes. In this study, we report that the expression of MED16 is markedly decreased in papillary thyroid cancer (PTC) tumors compared with normal thyroid tissues. In vitro, MED16 overexpression in PTC cells significantly inhibited cell migration, enhanced sodium/iodide symporter expression and iodine uptake, and decreased resistance to radioactive 131I (RAI). Conversely, PTC cells in which MED16 had been further knocked down (MED16KD) exhibited enhanced cell migration, epithelial–mesenchymal transition, and RAI resistance, accompanied by decreased sodium/iodide symporter levels. Moreover, cell signaling through transforming growth factor β (TGF-β) was highly activated after the MED16 knockdown. Similar results were obtained in MED12KD PTC cells, and a co-immunoprecipitation experiment verified interactions between MED16 and MED12 and between MED16 and TGF-βR2. Of note, the application of LY2157299, a potent inhibitor of TGF-β signaling, significantly attenuated MED16KD-induced RAI resistance both in vitro and in vivo. In conclusion, our findings indicate that MED16 reduction in PTC contributes to tumor progression and RAI resistance via the activation of the TGF-β pathway.

scholarly journals Ultrasonographic Characteristics of the Follicular Variant Papillary Thyroid Cancer According to the Tumor Size

2016 ◽  
Vol 31 (3) ◽  
pp. 397 ◽  
Author(s):  
Eon Ju Jeon ◽  
Young Ju Jeong ◽  
Sung Hwan Park ◽  
Chang Ho Cho ◽  
Ho Sang Shon ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Tumor Size ◽  
Papillary Thyroid ◽  
Follicular Variant
Sign in / Sign up

Export Citation Format

Share Document